earnings
confidence high
sentiment positive
materiality 0.80
BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance
BIOMARIN PHARMACEUTICAL INC
2024-Q3 EPS reported
$1.56
revenue$2,106,602,000
- Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.
- GAAP diluted EPS $0.55 (+162%); Non-GAAP diluted EPS $0.91 (+98%).
- Raised full-year 2024 guidance for total revenue, Non-GAAP operating margin, and Non-GAAP EPS.
- Retired $495M convertible debt in cash, eliminating ~4M dilutive shares.
- Over 3,800 children on VOXZOGO; majority of US new starts under age 5.